Prevention and management of cardiovascular disease in adults with cancer: an International Cardio-Oncology Society (IC-OS) and Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement
Open Access
- 29 May 2026
- journal article
- review article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (6) , 590
Abstract
Purpose Cardiovascular (CV) toxicity is prevalent in cancer survivors due to shared risk factors, direct CV injury from cancer therapy (CT), and development/exacerbation of CV risk factors during treatment. Succinct guidance on the minimum standard of CV care required of cancer care providers (CCPs) can improve outcomes for survivors. This clinical practice statement (CPS) is aimed at CCPs focused on identification, prevention, and management of CVD in individuals with cancer. Methods The International Cardio-Oncology Society and Multinational Association of Supportive Care in Cancer identified members with expertise across oncology, cardiology, and cancer survivorship. Key questions/areas of practice recommendations related to CV risk and CVD were identified across the cancer trajectory.Working groups performed targeted literature reviews and consensus was reached for all recommendations. Results 5 over-arching clinical practice recommendations for CCPs were identified: (1) perform a CV risk assessment prior to starting CT (2) identify and facilitate CV-related care during CT; (3) ensure measures are taken to mitigate the risk of cancer therapy related CV toxicity (CTR-CVT) prior to and during CT; (4) monitor CV status and risk factors during therapy and refer to the appropriate health care provider if CV risk factors are uncontrolled or new signs/symptoms develop; and (5) re-assess CV risk following completion of CT (periodically for those with advanced disease on life long treatment) and develop a CV surveillance plan. Conclusions CCPs play a pivotal role in identifying and addressing CTR-CVT. This CPS provides specific, succinct, and actionable behaviours that can be readily implemented in cancer care globally. Graphical Abstract The alternative text for this image may have been generated using AI.Keywords
Funding Information
- University of New South Wales
This publication has 41 references indexed in Scilit:
- Diagnosis and Management of Cardiovascular Adverse Effects of Targeted Oncology Therapies: Bruton’s Tyrosine Kinase, Immune Checkpoint, and Vascular Endothelial Growth Factor Inhibitors: 2025 ACC Concise Clinical GuidanceJACC, 2025
- Reducing the impact of cardiovascular disease in older people with cancer: a qualitative study of healthcare providersJournal of Cancer Survivorship, 2023
- Global Longitudinal Strain for the Early Detection of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysisClinical Oncology, 2022
- Role of Serum Biomarkers in Cancer Patients Receiving Cardiotoxic Cancer Therapies: A Position Statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of CardiologyEuropean Journal of Heart Failure, 2020
- Role of Cardiovascular Imaging in Cancer Patients Receiving Cardiotoxic Therapies: A Position Statement on Behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)European Journal of Heart Failure, 2020
- Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology SocietyEuropean Journal of Heart Failure, 2020
- Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendationsAnnals of Oncology, 2020
- A Cardio-Oncology Cardiovascular Prevention FrameworkJACC: Cardiooncology, 2019
- Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast CancerJACC: Cardiooncology, 2019
- Use of Myocardial Strain Imaging by Echocardiography for the Early Detection of Cardiotoxicity in Patients During and After Cancer ChemotherapyJACC, 2014